Investigational Drug Information for Tropifexor
✉ Email this page to a colleague
What is the drug development status for Tropifexor?
Tropifexor is an investigational drug.
There have been 7 clinical trials for Tropifexor.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 9th 2015.
The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Liver Cirrhosis. The leading clinical trial sponsors are Novartis Pharmaceuticals, Allergan, and [disabled in preview].
Summary for Tropifexor
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 17 |
| WIPO Patent Applications | 20 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2015-09-09) |
| Vendors | 41 |
Recent Clinical Trials for Tropifexor
| Title | Sponsor | Phase |
|---|---|---|
| Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH) | Novartis Pharmaceuticals | Phase 2 |
| The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor. | Novartis Pharmaceuticals | Phase 1 |
| Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis. | Novartis Pharmaceuticals | Phase 2 |
Clinical Trial Summary for Tropifexor
Top disease conditions for Tropifexor
Top clinical trial sponsors for Tropifexor
US Patents for Tropifexor
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
